Activating mutations in PIK3CA, the gene encoding the p110α catalytic domain of PI3K, is one of the frequently altered genes in HR+ breast cancer (~40%) and is implicated in resistance to therapy [11,12,13]. The gene discussed is PIK3CG; the disease is breast cancer.